US7867001049 - Common Stock
SAGIMET BIOSCIENCES INC-A
NASDAQ:SGMT (9/6/2024, 8:00:02 PM)
After market: 2.65 +0.13 (+5.16%)2.52
-0.15 (-5.62%)
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
SAGIMET BIOSCIENCES INC-A
155 Bovet Rd., Suite 303
San Mateo CALIFORNIA
P: 16505618600
Employees: 10
Website: https://sagimet.com/
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sagimet Biosciences (NASDAQ:SGMT) just reported results for the second quarter ...
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress ...
Here you can normally see the latest stock twits on SGMT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: